{"DataElement":{"publicId":"5040180","version":"1","preferredName":"Acute Graft Versus Host Disease Stage Liver Severity Type","preferredDefinition":"A description of acute graft versus host disease liver severity stage.","longName":"5040172v1.0:2797650v1.5","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"5040172","version":"1","preferredName":"Acute Graft Versus Host Disease Stage","preferredDefinition":"A syndrome of immunologically mediated tissue damage that may occur following an allogeneic transplant, usually affecting the skin, liver, and GI tract. The onset is usually within one hundred days of transplantation or immunologic manipulation._Any distinct time period in a sequence of events.","longName":"2512823v1.0:4843953v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2512823","version":"1","preferredName":"Acute Graft Versus Host Disease","preferredDefinition":"A graft versus host disease with symptoms appearing within the first 100 days post-transplant, but with short duration.","longName":"C4980","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Graft Versus Host Disease","conceptCode":"C4980","definition":"A syndrome of immunologically mediated tissue damage that may occur following an allogeneic transplant, usually affecting the skin, liver, and GI tract. The onset is usually within one hundred days of transplantation or immunologic manipulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B898438-B0B8-35BB-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-21","endDate":null,"createdBy":"UMLLOADER_AGNIS","dateCreated":"2006-08-21","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"4843953","version":"1","preferredName":"Stage","preferredDefinition":"Any distinct time period in a sequence of events.","longName":"C48308","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage","conceptCode":"C48308","definition":"Any distinct time period in a sequence of events.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"177D51D9-1D88-7367-E050-BB89AD433961","latestVersionIndicator":"Yes","beginDate":"2015-06-01","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-06-01","modifiedBy":"ONEDATA","dateModified":"2015-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435022","version":"1","preferredName":"Disease, Disorder or Finding","preferredDefinition":"Specification of human conditions relevant to cancer. This includes observations, test results, history, and other concepts relevant to characterization of human cancer-related conditions. Non-neoplastic conditions of interest are also included.","longName":"C7057","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D9-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"23428223-EDB0-0C35-E050-BB89AD430FC5","latestVersionIndicator":"Yes","beginDate":"2015-10-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-10-29","modifiedBy":"NYCHM","dateModified":"2017-01-31","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2797650","version":"1.5","preferredName":"Acute Graft Versus Host Disease Liver Severity Type","preferredDefinition":"A syndrome of immologically mediated tissue damage occurring following allogeneic transplant usually affecting the skin, liver, and gi tract.  Onset is usually within one hundred days of transplantation or immunologic manipulation._A triangular-shaped organ located under the diaphragm in the right hypochondrium.  It is the largest internal organ of the body, weighting up to 2 kg.  Metabolism and bile secretion are its main functions.  It is composed of cells which have the ability to regenerate._Used of the degree of something undesirable e.g. pain or weather; also, strictness._Type; a subdivision of a particular kind of thing.","longName":"2797650v1.5","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"68","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Stage 4","valueDescription":"AGVHD Liver Stage 4","ValueMeaning":{"publicId":"5132191","version":"1","preferredName":"AGVHD Liver Stage 4","longName":"5132191","preferredDefinition":"Bilirubin > 15.0 mg/dL (> 256 micromol/L)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C874053-14E7-16D8-E050-BB89AD437237","latestVersionIndicator":"Yes","beginDate":"2016-02-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C874053-1500-16D8-E050-BB89AD437237","beginDate":"2016-02-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-24","modifiedBy":"ONEDATA","dateModified":"2016-02-24","deletedIndicator":"No"},{"value":"Stage 3","valueDescription":"AGVHD Liver Stage 3","ValueMeaning":{"publicId":"5132192","version":"1","preferredName":"AGVHD Liver Stage 3","longName":"5132192","preferredDefinition":"Bilirubin 6.1-15.0 mg/dL (104-256 micromol/L)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C874053-150A-16D8-E050-BB89AD437237","latestVersionIndicator":"Yes","beginDate":"2016-02-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C874053-1523-16D8-E050-BB89AD437237","beginDate":"2016-02-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-24","modifiedBy":"ONEDATA","dateModified":"2016-02-24","deletedIndicator":"No"},{"value":"Stage 2","valueDescription":"AGVHD Liver Stage 2","ValueMeaning":{"publicId":"5132193","version":"1","preferredName":"AGVHD Liver Stage 2","longName":"5132193","preferredDefinition":"Bilirubin 3.1-6.0 mg/dL (53-103 micromol/L)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C874053-152D-16D8-E050-BB89AD437237","latestVersionIndicator":"Yes","beginDate":"2016-02-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C874053-1546-16D8-E050-BB89AD437237","beginDate":"2016-02-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-24","modifiedBy":"ONEDATA","dateModified":"2016-02-24","deletedIndicator":"No"},{"value":"Stage 1","valueDescription":"AGVHD Liver Stage 1","ValueMeaning":{"publicId":"5132194","version":"1","preferredName":"AGVHD Liver Stage 1","longName":"5132194","preferredDefinition":"Bilirubin 2.0-3.0 mg/dL (34-52 micromol/L)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C874053-1550-16D8-E050-BB89AD437237","latestVersionIndicator":"Yes","beginDate":"2016-02-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C874053-1569-16D8-E050-BB89AD437237","beginDate":"2016-02-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-24","modifiedBy":"ONEDATA","dateModified":"2016-02-24","deletedIndicator":"No"},{"value":"Stage 0","valueDescription":"AGVHD Liver Stage 0","ValueMeaning":{"publicId":"5132195","version":"1","preferredName":"AGVHD Liver Stage 0","longName":"5132195","preferredDefinition":"No liver acute GVHD / bilirubin < 2.0 mg/dL (< 34 micromol/L)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C874053-1573-16D8-E050-BB89AD437237","latestVersionIndicator":"Yes","beginDate":"2016-02-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C874053-158C-16D8-E050-BB89AD437237","beginDate":"2016-02-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-24","modifiedBy":"ONEDATA","dateModified":"2016-02-24","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2797649","version":"1","preferredName":"Acute Graft Versus Host Disease Liver Severity Type","preferredDefinition":"A syndrome of immologically mediated tissue damage occurring following allogeneic transplant usually affecting the skin, liver, and gi tract.  Onset is usually within one hundred days of transplantation or immunologic manipulation.:A large organ located in the upper abdomen. The liver cleanses the blood and aids in digestion by secreting bile.:Severity; used of the degree of something undesirable e.g. pain or weather.:Type; a subdivision of a particular kind of thing.","longName":"C4980:C12392:C25676:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Graft Versus Host Disease","conceptCode":"C4980","definition":"A syndrome of immunologically mediated tissue damage that may occur following an allogeneic transplant, usually affecting the skin, liver, and GI tract. The onset is usually within one hundred days of transplantation or immunologic manipulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Liver","conceptCode":"C12392","definition":"A triangular-shaped organ located under the diaphragm in the right hypochondrium. It is the largest internal organ of the body, weighting up to 2 kg. Metabolism and bile secretion are its main functions. It is composed of cells which have the ability to regenerate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Severity","conceptCode":"C25676","definition":"Used of the degree of something undesirable e.g. pain or weather; also, strictness.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AF59D42-C7E2-3B75-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-11-05","endDate":null,"createdBy":"NYCHM","dateCreated":"2008-11-05","modifiedBy":"ONEDATA","dateModified":"2008-11-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"23428223-ECB4-0C35-E050-BB89AD430FC5","latestVersionIndicator":"Yes","beginDate":"2015-10-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-10-29","modifiedBy":"NYCHM","dateModified":"2017-01-31","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2793652","version":"1","longName":"PhenX","context":"PhenX","ClassificationSchemeItems":[{"publicId":"4809631","version":"1","longName":"Sickle Cell Disease Collection","context":"PhenX"},{"publicId":"7765018","version":"1","longName":"Curative Therapies","context":"PhenX"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685478","version":"1","longName":"Testing Set â€“ Moderately Different","context":"NCIP"}]}],"AlternateNames":[{"name":"PhenX","type":"USED_BY","context":"PhenX"},{"name":"HPST_AGHD_agvhd_stge_liver","type":"NMDP_FN","context":"NHLBI"},{"name":"TPST_GVHD_agvhd_stge_liver","type":"NMDP_FN","context":"NHLBI"},{"name":"CPST_GVHD_agvhd_stge_liver","type":"NMDP_FN","context":"NHLBI"},{"name":"PerformedClinicalInterpretation:severityCode","type":"HCT_BRIDG_5","context":"NHLBI"},{"name":"TPST_GVHD_dx_agvhd_stge_liver","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What was the acute graft vers","type":"Preferred Question Text","description":"What was the acute graft versus host disease liver severity stage?","url":null,"context":"NHLBI"},{"name":"Liver","type":"Alternate Question Text","description":"Liver","url":null,"context":"NHLBI"},{"name":"Liver","type":"Application Standard Question Text","description":"Liver","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"23432AFA-C95B-A610-E050-BB89AD434BE1","latestVersionIndicator":"Yes","beginDate":"2015-10-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-10-29","modifiedBy":"PANH","dateModified":"2021-08-13","changeDescription":"Added HCT_BRIDG5 alternate name - RR 2018-12-21 Added FN for 2450. AK 6/6/19","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}